New scan may reveal brain tumor drug effects in weeks, not years

This study looks at whether a special PET scan (18F-AGX) can detect early changes in brain tumor activity in adults with slow-growing IDH-mutant gliomas who are taking the drug Vorasidenib. Ten participants will get the drug daily for about a year and have multiple PET and MRI scans to see if metabolic changes predict tumor shrinkage or growth. The goal is to find a faster way to tell if the treatment is working, instead of waiting months or years for standard MRI results.